ATE493652T1 - Quantitative assays für pdgfr-beta- in körperflüssigkeiten - Google Patents
Quantitative assays für pdgfr-beta- in körperflüssigkeitenInfo
- Publication number
- ATE493652T1 ATE493652T1 AT06801170T AT06801170T ATE493652T1 AT E493652 T1 ATE493652 T1 AT E493652T1 AT 06801170 T AT06801170 T AT 06801170T AT 06801170 T AT06801170 T AT 06801170T AT E493652 T1 ATE493652 T1 AT E493652T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- diseases
- body fluid
- patient
- monitor
- Prior art date
Links
- 210000001124 body fluid Anatomy 0.000 title abstract 3
- 239000010839 body fluid Substances 0.000 title abstract 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 title 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 title 1
- 238000012207 quantitative assay Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 abstract 3
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 239000002870 angiogenesis inducing agent Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 102000027450 oncoproteins Human genes 0.000 abstract 1
- 108091008819 oncoproteins Proteins 0.000 abstract 1
- 230000001855 preneoplastic effect Effects 0.000 abstract 1
- 238000011002 quantification Methods 0.000 abstract 1
- -1 such as Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/49—Platelet-derived growth factor [PDGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70780605P | 2005-08-11 | 2005-08-11 | |
| PCT/US2006/031245 WO2007021860A2 (en) | 2005-08-11 | 2006-08-10 | QUANTITATIVE ASSAYS FOR PDGFR-β IN BODY FLUIDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE493652T1 true ATE493652T1 (de) | 2011-01-15 |
Family
ID=37758168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06801170T ATE493652T1 (de) | 2005-08-11 | 2006-08-10 | Quantitative assays für pdgfr-beta- in körperflüssigkeiten |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070037224A1 (de) |
| EP (1) | EP1913391B1 (de) |
| AT (1) | ATE493652T1 (de) |
| DE (1) | DE602006019262D1 (de) |
| WO (1) | WO2007021860A2 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144144A0 (en) * | 1999-01-13 | 2002-05-23 | Bayer Ag | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| WO2003068228A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| NZ626589A (en) * | 2003-02-21 | 2016-01-29 | Resmed Ltd | Nasal assembly |
| US7557129B2 (en) * | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| US7191068B2 (en) * | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
| US8068990B2 (en) * | 2003-03-25 | 2011-11-29 | Hologic, Inc. | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids |
| DE602004011340T2 (de) * | 2003-05-20 | 2008-11-06 | Bayer Healthcare Llc | Diaryl-harnstoffe mit kinasehemmender wirkung |
| EP1946115A4 (de) * | 2005-10-21 | 2009-12-02 | Bayer Healthcare Llc | Verfahren zur vorhersage und prognose von krebs und überwachung der krebstherapie |
| WO2008120107A2 (en) * | 2007-04-03 | 2008-10-09 | Oxyrane (Uk) Limited | Glycosylation of molecules |
| WO2009137666A2 (en) * | 2008-05-08 | 2009-11-12 | The Trustees Of The University Of Pennsylvania | Chemiluminescence enhanced detection |
| US8741287B2 (en) * | 2008-06-18 | 2014-06-03 | Abbott Laboratories | PlGF-1 assay and kits and components thereof |
| MX2010014228A (es) * | 2008-06-18 | 2011-03-29 | Abbott Laboratories Star | Metodos y productos de diagnostico del p/gf-1 acompañante. |
| US20100004306A1 (en) * | 2008-06-18 | 2010-01-07 | Abbott Laboratories | PIGF-1 Assay and kits and components thereof |
| AU2009291203B2 (en) * | 2008-09-10 | 2015-01-22 | Life & Brain Gmbh | Peripheral zone tumor cells, methods for their preparation and use |
| ES2644725T3 (es) | 2009-03-19 | 2017-11-30 | Universite D'angers | Método no invasivo para evaluar la progresión de la fibrosis hepática |
| CN102445543B (zh) * | 2010-10-08 | 2014-03-12 | 中国医学科学院肿瘤研究所 | 辅助诊断肺癌淋巴结转移的试剂 |
| GB201204014D0 (en) * | 2012-03-07 | 2012-04-18 | Univ Leeds | Diagnostic marker compounds and their use |
| WO2014145181A1 (en) * | 2013-03-15 | 2014-09-18 | Morphotek, Inc. | Methods for determining prognosis of colorectal cancer |
| US10017823B2 (en) | 2013-04-25 | 2018-07-10 | Cbs Bioscience, Co., Ltd | Analytical method for increasing susceptibility of molecular targeted therapy in hepatocellular carcinoma |
| EP3491388B1 (de) | 2016-08-01 | 2021-09-01 | Centre Hospitalier Universitaire d'Angers | Multi-zielgerichteten fibrosetests |
| WO2020099487A1 (en) * | 2018-11-14 | 2020-05-22 | Vrije Universiteit Brussel | Soluble pdgfrbeta as a biomarker for fibrosis |
| KR102363980B1 (ko) * | 2020-04-13 | 2022-02-15 | 전남대학교산학협력단 | 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법 |
| US20230392209A1 (en) * | 2020-10-21 | 2023-12-07 | Prelude Corporation | Methods for treating a subject with local invasive breast cancer based on pdgfrb levels |
| CN116997566A (zh) * | 2021-03-19 | 2023-11-03 | 伊莱利利公司 | 用PDGFRα抑制剂治疗癌症的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4745181A (en) | 1986-10-06 | 1988-05-17 | Ciba Corning Diagnostics Corp. | Polysubstituted aryl acridinium esters |
| US6043211A (en) * | 1988-02-02 | 2000-03-28 | The Regents Of The University Of California | Method for inhibiting the activity of a platelet-derived growth factor receptor binding protein |
| US6110737A (en) * | 1988-02-02 | 2000-08-29 | The Regents Of The University Of California | Human platelet-derived growth factor receptor, type A |
| US6228600B1 (en) * | 1992-07-20 | 2001-05-08 | The United States Of America As Represented By The Department Of Health And Human Services | Immunoassays for the alpha platelet-derived growth factor receptor |
| US5468468A (en) * | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
| JP2640568B2 (ja) * | 1989-02-09 | 1997-08-13 | アメリカ合衆国 | タイプα血小板由来増殖因子レセプター遺伝子 |
| DE69011329T2 (de) * | 1989-05-22 | 1994-12-08 | Zymogenetics, Inc., Seattle, Wash. | Pdgf-alpha-rezeptor. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5817310A (en) * | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
| US5395752A (en) | 1993-03-19 | 1995-03-07 | Ciba Corning Diagnostics Corp. | Long emission wavelength chemiluminescent compounds and their use in test assays |
| US6264949B1 (en) * | 1998-09-29 | 2001-07-24 | Mount Sinai School Of Medicine Of New York University | Noninvasive agents for diagnosis and prognosis of the progression of fibrosis |
| DE60329020D1 (de) * | 2002-03-01 | 2009-10-08 | Siemens Healthcare Diagnostics | Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von körperflüssigkeiten |
| DE602004011340T2 (de) * | 2003-05-20 | 2008-11-06 | Bayer Healthcare Llc | Diaryl-harnstoffe mit kinasehemmender wirkung |
| WO2005015236A2 (en) * | 2003-07-18 | 2005-02-17 | Roche Diagnostics Gmbh | A method for predicting the progression of adenocarcinoma |
-
2006
- 2006-08-10 WO PCT/US2006/031245 patent/WO2007021860A2/en active Application Filing
- 2006-08-10 EP EP06801170A patent/EP1913391B1/de not_active Not-in-force
- 2006-08-10 DE DE602006019262T patent/DE602006019262D1/de active Active
- 2006-08-10 AT AT06801170T patent/ATE493652T1/de not_active IP Right Cessation
- 2006-08-10 US US11/502,013 patent/US20070037224A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007021860B1 (en) | 2008-02-28 |
| DE602006019262D1 (de) | 2011-02-10 |
| EP1913391A2 (de) | 2008-04-23 |
| US20070037224A1 (en) | 2007-02-15 |
| EP1913391B1 (de) | 2010-12-29 |
| EP1913391A4 (de) | 2009-02-18 |
| WO2007021860A3 (en) | 2007-10-04 |
| WO2007021860A2 (en) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE493652T1 (de) | Quantitative assays für pdgfr-beta- in körperflüssigkeiten | |
| Bahadır et al. | Applications of electrochemical immunosensors for early clinical diagnostics | |
| DE602006018578D1 (de) | Diagnose- und prognoseverfahren von blasenkrebs. | |
| EP2293076A3 (de) | Verwendung von Procalcitonin zur Risikoeinteilung von Patienten mit einer primären, nicht-infektiösen Krankheit | |
| EA201390150A1 (ru) | Способы выявления сигнатур заболевания или патологических состояний в текучих средах организма | |
| ATE554386T1 (de) | Verbesserte immunoassayverfahren | |
| JP2017215338A5 (de) | ||
| WO2004058044A3 (en) | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor | |
| EP3708682A3 (de) | Verwendung von mikrovesikeln bei der diagnose und prognose von medizinischen krankheiten und leiden | |
| RU2018101257A (ru) | Способ детекции нуклеосом, содержащих гистоновые варианты | |
| CN102292637A (zh) | 用于检测或监测急性肾损伤的方法、装置和试剂盒 | |
| BRPI1007321A2 (pt) | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. | |
| MX342791B (es) | Ensayo elisa para la detección de vegf. | |
| WO2007146668A3 (en) | Use of imp3 as a prognostic marker for cancer | |
| TR201900083T4 (tr) | İnsan idrarının toplanmasına ve analizine yönelik aparat. | |
| ATE542139T1 (de) | Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit | |
| O’Byrne et al. | Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma | |
| Krajnak et al. | Biological effects of inhaled hydraulic fracturing sand dust. VI. Cardiovascular effects | |
| FR2919061B1 (fr) | Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal. | |
| Coskun et al. | Activation markers in Behçet's disease | |
| Dalirsani et al. | Comparison of Matrix Metalloproteinases 2 and 9 Levels in Saliva and Serum of Patients with Head and Neck Squamous Cell Carcinoma and Healthy Subjects. | |
| ATE476652T1 (de) | Quantitative assays für ras p21 in körperflüssigkeiten | |
| Galliera et al. | Circulating sRAGE in the diagnosis of osteolytic bone metastasis | |
| BRPI0610267B8 (pt) | métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método | |
| RU2006104863A (ru) | Способ ранней диагностики рака предстательной железы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |